samedan logo
 
 
 
spacer
home > ebr > spring 2003 > meptides: a novel class of synthetic peptide derivatives for the potential treatment of neurodegenerative diseases
PUBLICATIONS
European Biopharmaceutical Review

Meptides: A Novel Class of Synthetic Peptide Derivatives for the Potential Treatment of Neurodegenerative Diseases

A number of seemingly unrelated neurodegenerative diseases, including Alzheimer's, Parkinson's and Huntington's diseases, CJD (the human form of 'mad cow' disease) and ALS (motor neurone disease) have all recently been linked to a common pathogenic process called amyloidosis. In each case a specific protein or peptide clumps together in a specific part of the brain to form toxic soluble oligomers and/or insoluble fibres, which are widely believed to cause the progressive degeneration of neurons associated with these diseases. Several academic groups and at least one biotech company are now working on a novel class of synthetic peptide derivatives ('meptides') which can inhibit and reverse this process of protein/peptide aggregation in vitro, and which have the potential to yield effective treatments or perhaps even outright cures for all these diseases.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Kelvin Stott, Chief Scientific Officer, and Andrew J Doig, Research Director, at Senexis Limited

Kelvin Stott is the Chief Scientific Officer and a Co-Founder of Senexis Limited. Before forming Senexis, he gained his PhD and studied the mechanism of Huntington's disease as a Research Fellow at Cambridge University. He then spent two years working in the pharmaceutical sector as a management consultant at McKinsey & Company.


Andrew J Doig is a Senior Lecturer in the Department of Biomolecular Sciences at UMIST and Research Director of Senexis. He undertook research at Cambridge and Stanford Universities before taking a lectureship at UMIST in 1994. His research interests include protein structure and bioinformatics, as well as amyloid.

spacer
Kelvin Stott
spacer
spacer
spacer
Andrew J Doig
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

TAGRISSOTM (osimertinib) DEMONSTRATED UNPRECEDENTED DISEASE-FREE SURVIVAL IN THE ADJUVANT TREATMENT OF STAGE IB-IIIA COMPLETELY RESECTED PATIENTS WITH EGFR MUTATION

Detailed results from the Phase III ADAURA trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumour resection with curative intent.
More info >>

White Papers

Digital Transformation of the Cold Chain

Sensitech EMEA

The Life Sciences cold chain is a seamless and interconnected global network of people, equipment, data and processes that helps to ensure the safety and integrity of our medicines and vaccines. Cold chain logistics spending totaled $13 billion in 2017, an investment designed to protect some $283 billion in Life Sciences cold chain products, growing at 19% annually.1 Sensitech Inc., a part of UTC Climate, Controls & Security, a unit of United Technology Corp., has played an essential part in the Life Sciences cold chain since 1990, providing a comprehensive set of solutions for manufacturers of biologics, prescription pharmaceuticals, clinical trial materials, and over-the-counter drugs. These solutions help to ensure product quality, patient safety, and regulatory compliance while helping to prevent theft and optimizing cold chain performance.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement